04/29/2024

Using an AI algorithm to predict possible MSI high status in prostate cancer patients from digital pathology images

Tissue sequencing in prostate cancer is often challenging because of limitations of tumor quantity or tissue quality; bone metastases are frequent. It is critical to identify whether patients are MSI-H since they may be eligible for immunotherapy and/or may need workup for Lynch syndrome.
Authors Nike Beaubier, MD
SVP of Life Sciences and Pathology, Tempus

With our ability to digitize pathology slides and use AI to garner insights from these images, we can support efficient use of tissue while also helping to surface appropriate patients for dMMR/MSI-H testing to ensure guideline-directed care for those with relevant alterations. 

Nike Beaubier, MD and SVP of Life Sciences and Pathology shares her perspective on these issues and how Tempus’ newly launched p-MSI algorithm has helped predict MSI-H status for prostate cancer patients who otherwise may not have received MSI results.

Combining AI algorithms and digital pathology can streamline the diagnosis and treatment of prostate cancer patients

Tissue sequencing in prostate cancer is challenging because tumor content is often low, and metastases are predominantly in the bone, particularly in the later stages of disease. The prevalence of the tissue-agnostic biomarker microsatellite instability-high (MSI-H) / deficiency in mismatch repair (dMMR) in prostate cancer is approximately 2-3%1,2.

Many prostate cancer patients do not currently receive MSI status results from NGS sequencing because of sample quantity or quality issues. The tumor fraction must be ≥ 30% on a successful sequencing run for the NGS MSI-H algorithm to produce a result.

It is critical to identify whether patients are MSI-H in metastatic prostate cancer, since this patient population may be eligible for immunotherapy. Response rates as high as 50% have been observed when dMMR/MSI-H prostate cancer patients are treated with immune checkpoint inhibitors (ICI), making the case for MSI-H testing as a gateway to these patients accessing beneficial therapies.2

Early-stage prostate cancer patients can also benefit from knowing their MSI status because many dMMR/MSI-H cases are due to Lynch syndrome, so they and their families may benefit from genetic testing and cancer screening.


“At Tempus we’ve been sequencing patients for years, so we have rich matched molecular data—including RNA whole transcriptome data—and hundreds of thousands of whole slide images. Combining de-identified data from an imaging library and a molecular library enables Tempus to create AI-driven models that can provide insights which would be unimaginable in any other way.”Nike Beaubier, MD and SVP of Life Sciences and Pathology


Tempus’ p-MSI algorithm predicts patients with prostate cancer who may be MSI-H

Tempus has developed p-MSI, a novel digital pathology algorithm to surface prostate cancer patients who are more likely than average to be MSI-H and who should be considered for confirmatory testing. 

The p-MSI algorithm runs on digital images of hematoxylin and eosin (H&E) stained slides and therefore does not consume tissue to run since the H&E is already required for diagnosis. Upon scanning the H&E, the algorithm predicts whether a  patient is more likely than the typical prostate cancer patient to be MSI-H/dMMR. Then, informed by this prediction, the treating oncologist or urologist can opt to do confirmatory testing such as immunohistochemistry (IHC) staining for MMR proteins. If IHC is selected as the modality for confirmatory testing, as few as 100 cells/slide can yield a result—significantly below what is required for next-generation sequencing (NGS)

By identifying an enriched population of prostate cancer patients who are more likely to be MSI-H, Tempus is helping to direct patients towards targeted treatments.

The mismatch repair protein IHC panel (MLH1, PMS2, MSH2, MSH6) is widely available, supporting broad access to confirmatory testing. As a result, the insight gained from running p-MSI on patient samples isn’t just nice to have, it’s actionable.

The synergy between digital pathology and AI can transform the future of precision medicine

Although the human eye and brain are remarkable at analyzing images, AI algorithms can  detect patterns the human eye does not. Recently, AI has proven beneficial in analyzing text and deriving insights from textual data. Images are far more data dense than text, meaning AI has a rich data source to work with when analyzing images for deeper patterns and insights. Furthermore, AI has a significantly higher processing capacity than the human brain and can analyze hundreds of thousands of features on a slide and tens of thousands of slides at a time. 

AI can not take the place of an expert pathologist; rather, it boosts their efficiency and accuracy, by offering insights beyond the ability of human visual analysis. Together, we believe pathologists and AI achieve outcomes superior to what either could do alone.

Practically speaking, Tempus has a unique infrastructure to leverage AI algorithms within digital pathology to augment clinical practice. Tempus has been sequencing patients for years and has always scanned slides, so we have a rich library of matched molecular data—including RNA whole transcriptome data—and hundreds of thousands of whole slide images. Using these de-identified molecular datasets, the research team can train imaging models from molecular labels, and the algorithms can look for imaging features across hundreds of thousands of cases to recognize patterns. Combining de-identified data from an imaging library and a molecular library enables Tempus to create AI-driven models that can provide insights which would be unimaginable in any other way.

Using AI algorithms alongside digital pathology will help catalyze advances in precision medicine that will improve clinical practice over time. Radiology workflows have been digitized for many years, with images of tissue captured directly by CCD cameras, to great benefit. However, pathology images can not be captured directly from tissue; tissue must be fixed, processed, and stained on glass slides first. Thus, digital image capture has not universally been done at large scale. However, the advancement of AI algorithms, like the one described here, provides the incentive to do so. Pathologists and other patient care providers can generate insights using these digital images and bring patients closer to receiving the treatments they urgently need.

1. Hu, Q., Rizvi, A. A., Schau, G., Ingale, K., Muller, Y., Baits, R., … & Nagpal, K. (2023). Development and Validation of a Deep Learning-Based Microsatellite Instability Predictor from Prostate Cancer Whole-Slide Images. arXiv preprint arXiv:2310.08743.

2. Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801. PMID: 30589920; PMCID: PMC6459218.

Related Content

View more
  • post image
    05/24/2024

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • post image
    06/07/2024

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.

    LIVE WEBINAR

    Wednesday, July 31 @ 11am CT

    Integrating Omics in R&D: A new era of biomedical research

    Join us as we explore how multi-omics is reshaping the research landscape. Gain valuable insights from industry leaders as we: dive into the integration of diverse omics data, from NGS to proteomics, in research; discuss the transformative role of multi-omics in understanding complex disease mechanisms; and explore how multi-omics is personalizing clinical research for precision medicine.

    Read more
  • post image
    05/30/2024

    Accelerating ADC Development with Tempus AI

    Empowering precision and efficiency in ADC therapeutics with advanced data analytics

    Read more